High affinity integrin polypeptides and uses thereof

Details High affinity integrin polypeptides and uses thereof High affinity integrin polypeptides and uses thereof

2006-12-26

2006-12-26

Chan, Christina (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Chemical modification or the reaction product thereof, e.g.,...

C435S007100

Reexamination Certificate

active

07153944

ABSTRACT:
Polypeptides comprising all or part of a variant integrin α subunit A domain or a variant integrin β subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the high affinity form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in a lower affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit or any integrin β subunit and could be used therapeutically. The variant integrin polypeptides preferably include a ligand-binding portion of an A-domain or an A-like domain.

REFERENCES:
patent: 5985278 (1999-11-01), Mitjans et al.
patent: 2003/0078375 (2003-04-01), Arnaout et al.
patent: WO 02/04521 (2000-01-01), None
patent: WO 00/59878 (2000-10-01), None
patent: WO 00/60355 (2000-10-01), None
patent: WO 02/31511 (2002-04-01), None
Corbi et al. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem. Sep. 5, 1988;263(25):12403-11.
Baldwin et al., “Cation Binding to the Integrin CD11b I Domain and Activation Model Assessment” Structure 6:923-935, 1998.
Edwards et al., “Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted. . . ” J. of Biol. Chem. 273:28937-28944, 1998.
Emsley et al., “Structural Basis of Collagen Recognition by Integrin α2β1” Cell 100:47-56, 2000.
Emsley et al., “Crystal Structure of the I Domain from Integrin α2β1” J. of Biol Chem. 272:28512-28517, 1997.
Kamata et al., “Direct Binding of Collagen to the I Domain of Integrin α2β1 (VLA-2, CD49b/CD29). . . ”J. of Biol. Chem. 269:26006-26010, 1994.
Kern et al., “The Role of the I Domain in Ligand Binding of the Human Integrin α1β1” J. of Biol. Chem. 269:22811-22816, 1994.
Lee et al., “Crystal Structure of the A Domain from the α Subunit of Integrin CR3 (CD11/CD18)” Cell 80:631-638, 1995.
Lee et al., “Two Conformations of the Integrin A-Domain (1-Domain): A Pathway for Activation?” Structure 3:1333-1340, 1995.
Legge et al., “NMR Solution Structure of the Inserted Domain of Human Leukocyte Function Associate Antigen-1” J. Mol. Biol. 295:1251-1264, 2000.
Li et al., “Two Functional States of the CD11b A-Domain: Correlations with Key Features of Two. . . ” J. of Cell. Biol. 143:1523-1534, 1998.
Michishita et al., “A Novel Divalent Cation-Binding Site in the A Domain of the β2 Interin CR3. . . ” Cell 72:857-867, 1993.
Nolte et al., “Crystal Structure of the α1 β1 Integrin I-Domain: Insights into Integrin I-Domain Function” FEBS Letters 452:379-385, 1999.
Oxvig et al., “Conformational Changes in Tertiary Structure Near the Ligand Binding Site of an Integrin I Domain” Proc. Nat'l. Acad. Sci. USA 96:2215-2220, 1999.
Rieu et al., “Solvent-accessible Residues on the Metal Ion-dependent Adhesion Site Face of Integrin CR3. . . ” J. of Biol. Chem. 271:15858-15861, 1996.
Smith et al., “The Arg-Gly-Asp Binding Domain of the Vitronectin Receptor” J. of Biol. Chem. 263:18726-18731, 1988.
Zhang et al., “Amino Acid Sequences Within the α Subunit of Integrin αmβ2(Mac-1) Critical for Specific Recognition of C3bi” Biochemistry 38:8064-8071, 1999.
Zhang et al., “A Discrete Site Modulated Activation of I Domains” J. of Biol. Chem. 271:29953-29957, 1996.
Xiong et al., “An Isoleucine-based Allosteric Switch Controls Affinity. . . ” J. of Biol. Chem. 275:38762-38767, 2000.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activites..” J. Cell. Biol. 111:2129-2138, 1990.
Feng et al., “Peptides Derived from the Complementarity-determining Regions of Anti-Mac-1...” J. of Biol. Chem. 273:5625-5630, 1998.
Huth et al., NMR and Mutagenesis Evidence for and I Domain Allosteric Site...: Proc. Nat;l. Acad. Sci. 97(10):5235, 2000.
Lazar et al., “Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47...” Mol. Cell. Biol. 8:1247-1252, 1988.

Affiliated with

Also associated with

Rating

High affinity integrin polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High affinity integrin polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity integrin polypeptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3712932